Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

TAZ is indispensable for c-MYC-induced hepatocarcinogenesis

Journal of Hepatology(2021)10.1016/j.jhep.2021.08.021Source: DataRank Database

TAZ is indispensable for c-MYC-induced hepatocarcinogenesis is a research paper published in Journal of Hepatology (2021). On theSindex it has a DataRank of 0. It has been cited 95 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access95 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)Impact (FWCI 7.53)OA: greenTopics (78)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Shanshan Zhang ORCID,Yi Zhang ORCID,Jiaoyuan Jia,Jingxiao Wang ORCID,Xianqiong Liu

Live enrichment

PubMed:34464659 PMC:PMC9569156 OpenAlex:https://openalex.org/W3198862328

National Institutes of Health

Grant: P30DK026743

National Institutes of Health

Grant: R01CA204586

National Institutes of Health

Grant: R01CA239251

National Institutes of Health

Grant: R01CA250227

National Institutes of Health

Grant: R03CA288375

Deutsche Forschungsgemeinschaft

Grant: RI2695/1-1

National Natural Science Foundation of China

Grant: 82002967

NCI NIH HHS

Grant: U01 CA288375

National Institutes of Health

Grant: 5R01CA250227-04

Investigating multifactorial beta-catenin activation in hepatocellular cancers

National Institutes of Health

Grant: 5R01CA239251-02

Signaling pathways during hepatocarcinogenesis

Deutsche Forschungsgemeinschaft

Grant: unidentified

unidentified

National Institutes of Health

Grant: 5R01CA204586-05

Yap and beta-catenin interactions in liver: Implications in Pathophysiology

National Institutes of Health

Grant: 1U01CA288375-01

Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis

National Institutes of Health

Grant: 5P30DK026743-27

UCSF Liver Core Center

FWCI

7.53

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9569156

publisherhttps://api.elsevier.com/content/article/PII:S016882782102016X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S016882782102016X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jhep.2021.08.021

Fields of Study

Hippo pathway signaling and YAP/TAZCell death mechanisms and regulationLymphatic System and Diseases03 medical and health sciences0302 clinical medicineAnimalsCarcinoma, HepatocellularDNA-Binding ProteinsDisease Models, AnimalGene Regulatory NetworksLiver NeoplasmsMiceMice, KnockoutStatistics, NonparametricTranscription FactorsTranscriptional Coactivator with PDZ-Binding Motif ProteinsYAP-Signaling Proteins

MeSH Terms

YAP-Signaling ProteinsTranscriptional Coactivator with PDZ-Binding Motif ProteinsAnimalsDisease Models, AnimalDNA-Binding ProteinsCarcinoma, HepatocellularLiver NeoplasmsTranscription FactorsMice, KnockoutStatistics, NonparametricMiceGene Regulatory Networks

Keywords

Hippo signaling pathwayHCCSCancer researchGene silencingHepatocellular carcinomaConditional gene knockoutBiologyTranscription factorCarcinogenesisEffectorCell biologyGenec-mycYAPTazBcl2l12Liver Cancer790Carcinoma, HepatocellularKnockoutClinical Sciences610Statistics, NonparametricMiceRare DiseasesGenetics2.1 Biological and endogenous factorsAnimalsNonparametricGene Regulatory NetworksCancerMice, KnockoutBiomedical and Clinical SciencesGastroenterology & HepatologyAnimalLiver DiseaseCarcinomaStatisticsLiver NeoplasmsHepatocellularYAP-Signaling ProteinsDNA-Binding ProteinsDisease Models, AnimalTranscriptional Coactivator with PDZ-Binding Motif ProteinsDisease ModelsPublic Health and Health ServicesBCL2L12; c-MYC; Hepatocellular carcinoma; TAZ; YAP; Animals; Carcinoma, Hepatocellular; DNA-Binding Proteins; Disease Models, Animal; Gene Regulatory Networks; Liver Neoplasms; Mice; Mice, Knockout; Statistics, Nonparametric; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; YAP-Signaling ProteinsDigestive DiseasesTranscription Factors

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 9 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980622.v1figshare

Additional file 9 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980622figshare

Additional file 8 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980619.v1figshare

Additional file 8 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980619figshare

Additional file 7 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980616.v1figshare

Additional file 7 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980616figshare

Additional file 6 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980613.v1figshare

Additional file 6 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980613figshare

Additional file 5 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980610.v1figshare

Additional file 5 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980610figshare

Additional file 4 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980607.v1figshare

Additional file 4 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980607figshare

Additional file 3 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980604.v1figshare

Additional file 3 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980604figshare

Additional file 2 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980601.v1figshare

Additional file 2 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980601figshare

Additional file 1 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980598.v1figshare

Additional file 1 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980598figshare

Additional file 16 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980592.v1figshare

Additional file 16 of The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

10.6084/m9.figshare.19980592figshare